NasdaqGS:NBIXBiotechs
Neurocrine Biosciences (NBIX) Appoints Samir Siddhanti To Lead Growth After $2.9 Billion Deal
Neurocrine Biosciences (NasdaqGS:NBIX) has appointed Samir Siddhanti as Chief Business Officer.
He will lead business development, corporate strategy, and alliance management for the company.
The appointment follows Neurocrine Biosciences' recent US$2.9b acquisition of Soleno Therapeutics.
Neurocrine Biosciences focuses on treatments for neurological, endocrine, and psychiatric conditions, an area that continues to attract attention from larger pharma partners and investors. With Siddhanti...